Rapid Response Subunit Vaccine Design in the Absence of Structural Information

Prior to 2020, the threat of a novel viral pandemic was omnipresent but largely ignored. Just 12 months prior to the Coronavirus disease 2019 (COVID-19) pandemic our team received funding from the Coalition for Epidemic Preparedness Innovations (CEPI) to establish and validate a rapid response pipel...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in immunology 2020-11, Vol.11, p.592370-592370
Main Authors: Wijesundara, Danushka K, Avumegah, Michael S, Lackenby, Julia, Modhiran, Naphak, Isaacs, Ariel, Young, Paul R, Watterson, Daniel, Chappell, Keith J
Format: Article
Language:English
Subjects:
Animals
Arenaviridae
Civil Defense
Clinical Trials as Topic
COVID-19 Vaccines
Disease X
Drug Design
Humans
Immunology
membrane fusion protein
molecular clamp
Molecular Structure
Paramyxoviridae
Paramyxovirinae - immunology
pre-fusion conformation
subunit vaccine
Time Factors
Vaccines, Subunit - chemistry
Viral Vaccines
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Prior to 2020, the threat of a novel viral pandemic was omnipresent but largely ignored. Just 12 months prior to the Coronavirus disease 2019 (COVID-19) pandemic our team received funding from the Coalition for Epidemic Preparedness Innovations (CEPI) to establish and validate a rapid response pipeline for subunit vaccine development based on our proprietary Molecular Clamp platform. Throughout the course of 2019 we conducted two mock tests of our system for rapid antigen production against two potential, emerging viral pathogens, Achimota paramyxovirus and Wenzhou mammarenavirus. For each virus we expressed a small panel of recombinant variants of the membrane fusion protein and screened for expression level, product homogeneity, and the presence of the expected trimeric pre-fusion conformation. Lessons learned from this exercise paved the way for our response to COVID-19, for which our candidate antigen is currently in phase I clinical trial.
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2020.592370